openPR Logo
Press release

Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN

11-07-2024 06:46 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Biotech and Technology Giants Drive Innovation Across Pharma,

In a wave of groundbreaking developments, Cardiol Therapeutics Inc. (Nasdaq: CRDL), Modular Medical, Inc. (Nasdaq: MODD), and Cyngn Inc. (Nasdaq: CYN) each report advancements that promise to reshape the pharmaceutical, medical, and industrial automation landscapes.

Cardiol Therapeutics Progresses Orphan Drug Designation for CardiolRx Trademark

Cardiol Therapeutics (Nasdaq: CRDL) (TSX: CRDL), is advancing its CardiolRx Trademark drug candidate, which received Orphan Drug Designation (ODD) from the FDA for treating recurrent pericarditis, a rare inflammatory heart condition. This ODD status grants Cardiol Therapeutics advantages such as seven years of market exclusivity, tax credits, and fast-tracked reviews, positioning CardiolRx Trademark as a significant potential treatment in the cardiac space. Cardiol's MAVERIC clinical trial program, along with additional research targeting heart failure and acute myocarditis, exemplifies its strategic path forward. With ODD in place, Cardiol Therapeutics is moving CardiolRx Trademark along an accelerated regulatory pathway, aiming to transform treatments for rare cardiac diseases. See Entire News Article [https://cfnmedianews.com/cardiol-therapeutics-advancing-orphan-drug-trial-to-phase-2-3/].

Modular Medical's Pre-Clinical Success with GLP-1 Weight Loss Therapy

Modular Medical (Nasdaq: MODD) recently reported promising results from a pre-clinical study exploring a pump-based GLP-1 delivery system designed to enhance weight loss and glucose control. By combining a mealtime bolus with basal GLP-1 delivery, Modular Medical (Nasdaq: MODD) achieved a 17% weight reduction over 28 days, demonstrating a 25% improvement over basal delivery alone. CEO Jeb Besser emphasized plans to bring the innovative basal-bolus concept to human trials using the MODD1 device. This technology, with its dosing flexibility, aims to provide a tailored solution for metabolic therapy patients, especially those with sensitivity to side effects of long-acting GLP-1s.

Cyngn Inc. Expands Industrial Autonomy with Advanced Computer Vision

Cyngn Inc. (Nasdaq: CYN), recognized for its autonomous vehicle solutions in industrial applications, recently announced advancements in its computer vision (CV) technology within the DriveMod system. Leveraging NVIDIA's (NASDAQ: NVDA) accelerated computing and collaborating with notable partners like John Deere (NYSE: DE), DriveMod enhances industrial vehicle performance and intelligence. This technology is already deployed in material handling equipment from manufacturers such as BYD, Motrec, and Columbia Vehicle Group. A significant milestone in Cyngn's journey is its collaboration with Arauco, which led to a pre-order of 100 DriveMod-enabled forklifts. These advanced forklifts are equipped with capabilities like counting pallet stacks and detecting non-standard pallet pockets, setting new efficiency standards for industrial automation.

As each company pioneers' new frontiers in their respective fields, these advancements underscore the significant impact of innovation in healthcare, medical devices, and industrial automation, with far-reaching implications for patient care, personalized treatments, and efficient industrial operations.

Peraso Showcases 60 GHz Fixed Wireless Access for Urban Connectivity

Peraso Inc. (NASDAQ: PRSO), a leader in mmWave technology, will attend the 2024 AfricaTech Festival in Cape Town, South Africa, from November 11-14. Representing Canada at booth D2, Peraso aims to promote its 60 GHz Fixed Wireless Access (FWA) solutions designed for dense urban and rural settings. The technology offers high-speed, low-latency broadband connectivity, crucial for Africa's digital transformation. CEO Ron Glibbery highlighted growing demand across Africa for reliable gigabit connectivity and anticipates strong interest from industry leaders. Peraso's participation underscores its commitment to expanding digital access in underserved regions.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=biotech-and-technology-giants-drive-innovation-across-pharma-medical-devices-and-industrial-automation-crdl-modd-cyn]
Country: United States
Website: http://www.thestreetreports.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biotech and Technology Giants Drive Innovation Across Pharma, Medical Devices, and Industrial Automation CRDL, MODD, CYN here

News-ID: 3724091 • Views:

More Releases from ABNewswire

Realtor Agent in San Diego, CA Leverages Biotech and University Growth to Serve First-Time Homebuyers
Realtor Agent in San Diego, CA Leverages Biotech and University Growth to Serve …
San Diego, CA - A well-known real estate professional is capitalizing on San Diego's thriving biotech sector and university presence to create tailored services for first-time homebuyers entering the market. This strategic focus addresses the unique needs of young professionals and graduates establishing roots in the community. "San Diego's vibrant ecosystem of research institutions and biotech companies continues to drive substantial employment growth, creating a steady pipeline of well-qualified professionals looking
What Are Self-Tapping Threaded Inserts? Types, Installation, and Applications
What Are Self-Tapping Threaded Inserts? Types, Installation, and Applications
Image: https://ecdn6.globalso.com/upload/p/147/image_other/2025-08/picture-1.jpg When people are designing lightweight products, or repairing a worn-out thread, a dependable fastening tool can make a big difference. This is where self tapping threaded inserts can come into play. These inserts eliminate the need for pre-tapping and reduce installation time, as they are engineered to cut their own threads. They help reinforce assemblies, improve durability, and allow for repeated disassembly without degrading the holding strength, by forming secure
How To Choose Aluminum Profile For Folding Door
How To Choose Aluminum Profile For Folding Door
Why Aluminum Profiles [https://www.yx-aluminum.com/construction-aluminum-profile/] Matter for Folding Doors Aluminum profiles form the backbone of folding door, the right aluminum profile ensures smooth operation, proper weight distribution, and long-term performance, while the wrong choice can lead to sagging, difficulty in opening/closing, and premature wear. Image: https://ecdn6.globalso.com/upload/p/2279/image_other/2025-08/modern-design-interior-aluminum-doors-folding-doors-for-balcony-patio-courtyard-entrance.jpg Key Factors to Consider When Choosing Aluminum Profiles [https://www.yx-aluminum.com/products/] Alloy Grade The alloy grade determines the profile's strength, corrosion resistance, and workability: 6063: Most common for doors - excellent corrosion resistance
RUITE PUMP Delivers Custom 2-Inch Slurry Pumps to Copper Mine in Kazakhstan
RUITE PUMP Delivers Custom 2-Inch Slurry Pumps to Copper Mine in Kazakhstan
Image: https://www.ruitepumps.com/uploads/%E5%BE%AE%E4%BF%A1%E5%9B%BE%E7%89%87_20250710091254.jpg RUITE PUMP, a leading provider of robust and efficient pumping solutions, has successfully completed a custom order for a major copper mining operation in Kazakhstan. The order includes specially engineered 2-inch slurry pumps and a full set of wear parts, all meticulously designed to match the specific and demanding conditions of the client's site. The pumps, now ready for shipment, were developed following an in-depth analysis of the mine's operational

All 5 Releases


More Releases for Cardiol

CRDL Stock Price Reflects Investor Confidence in Cardiol Pipeline
Toronto, ON - May 20, 2025 - Cardiol Therapeutics Inc. (NASDAQ: CRDL), a clinical-stage biotech firm developing anti-inflammatory therapies for heart conditions, has provided recent updates highlighting progress in its clinical pipeline and corporate milestones aimed at delivering investor value. Steady Stock Performance and Financial Strength CRDL's stock price has demonstrated stability in recent trading, hovering around $1.10 per share. With a cash reserve of approximately $30.6 million, the company has funding
Cardiol Therapeutics (Nasdaq: CRDL) Advances Orphan Drug Designation for Cardiol …
Cardiol Therapeutics (NASDAQ: CRDL) presented breakthrough Phase II MAvERIC-Pilot data at the American Heart Association (AHA) Scientific Sessions 2024, showcasing CardiolRx Trademark as a potential game-changer for recurrent pericarditis treatment. The results revealed rapid pain relief within just 5 days and a dramatic reduction in pericarditis episodes, from 5.8 to 0.9 annually. CardiolRx Trademark also shows promise in treating myocarditis, a leading cause of sudden cardiac death in younger individuals. With
Pericarditis Drugs Market Is Expected To Reach $816.6 Million By 2031 - Kiniksa …
The latest report on Pericarditis Drugs Market offers valuable insights into emerging trends and pivotal developments within the market. It highlights significant growth opportunities that market participants can leverage, alongside strategic recommendations for capitalizing on these trends. This report serves as an indispensable tool for stakeholders seeking to deepen their understanding of the market landscape and identify actionable pathways for growth. By utilizing this in-depth analysis, stakeholders will gain the
A Comprehensive Study Exploring Myocarditis Treatment Market | Key Players Cardi …
Market Research Forecast published a new research publication on "Myocarditis Treatment Market Insights, to 2032" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Myocarditis Treatment market was mainly driven by the increasing R&D spending across the world. Some of the key players profiled in
Analysts Consensus Reaffirms Significant Upside Potential for Cardiol Therapeuti …
According to Gantoss, Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL) has many things going in its favor right now heading into a critical Phase 2 trial readout in RP in June that he believes will lead to a positive outcome. Cardiol Therapeutics (NASDAQ:CRDL) (TSX:CRDL), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, has been attracting substantial interest from investors
Myocarditis Market to Show Incremental Growth, estimates DelveInsight | Prominen …
DelveInsight's "Myocarditis Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Myocarditis, historical and forecasted epidemiology as well as the Myocarditis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Myocarditis market report provides current treatment practices, emerging drugs, Myocarditis market share of the individual therapies, current and forecasted Myocarditis market Size from 2017 to 2030 segmented by seven